Olaparib

So this was specifically using the platinum-based combination, so gemcarboinduction, which is one of the keynote 355 regimens, in patients irrespective of BRCA status.

And patients who had a response or had clinical benefit from that induction therapy were then eligible to be randomized to a continuation of their chemotherapy, so the Gemcarbo alongside Pembro, or to switch to Olaparib alongside Pembrolizumab.

And this study, again, which has been reported, you have the reference here, stopped after the phase two part.

It did not proceed to phase three, in part because the primary endpoint of an improvement with Olaparib versus chemotherapy was not observed.

The other important consideration that impacted this study was it was designed before we had the final results of Keynote 355.

And so patients did not have to have PD-L1 CPS greater than 10 to participate in this.

And so the study population would have required a reconsideration rather than flowing directly into phase three.

What we observed in the study is that Olaparib maintenance could be delivered in combination with pembrolizumab.

So if this were to prove successful, it would look a lot different than what we're seeing with the, with BMS, for instance, or Akeso, where they're just trying to displace.

AstraZeneca seems to be trying to take out or take off, you know, bite-sized chunks of different tumor types with different tumor-specific strategies, whether it be pairing, you know, in HER2 with another modality or in TIMsy with another modality, or looking at more targeted therapies like Tagrisso, Caliquper, Lynparza, and then many others that are currently in the pipeline, more than I could list off.

I mean, that when you look at their pipeline in oncology, there's a staggering number of different treatments that are currently in development across numerous tumor types.

So much more, I think, patchwork picture when you look at AstraZeneca's pipeline versus a, a BMS or a BioNTech or a Keso.

Dr. Hodgegaard also discusses the potential for selective PARP1 inhibitors in ovarian and breast cancer and where they could fit in the treatment regimen.

Firstly, for selective PARP1 inhibitors, where it precisely fits in currently remains to be seen, but for the EIC-1003 study, we had patients previously treated with a current generation PARP inhibitors, Olaparib, Rucaparib, Neuaparib and so forth.

And some of these patients also responded to treatment.

So this may represent another treatment opportunities for previously PARP inhibitor treated patients.